Pfizer Gross Margin 2010-2023 | PFE

Current and historical gross margin for Pfizer (PFE) over the last 10 years. The current gross profit margin for Pfizer as of December 31, 2023 is %.
Pfizer Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2023-12-31 $58.50B $33.54B 57.34%
2023-09-30 $68.54B $41.50B 60.55%
2023-06-30 $77.94B $54.11B 69.42%
2023-03-31 $92.95B $63.71B 68.54%
2022-12-31 $100.33B $65.99B 65.77%
2022-09-30 $99.88B $65.45B 65.53%
2022-06-30 $101.28B $62.98B 62.18%
2022-03-31 $92.43B $55.79B 60.35%
2021-12-31 $81.29B $50.47B 62.08%
2021-09-30 $68.88B $45.08B 65.45%
2021-06-30 $55.12B $39.25B 71.21%
2021-03-31 $46.08B $35.38B 76.78%
2020-12-31 $41.65B $33.17B 79.63%
2020-09-30 $32.07B $25.85B 80.62%
2020-06-30 $34.47B $27.66B 80.24%
2020-03-31 $37.87B $30.31B 80.03%
2019-12-31 $40.91B $32.85B 80.31%
2019-09-30 $40.22B $31.79B 79.05%
2019-06-30 $40.84B $32.32B 79.14%
2019-03-31 $41.04B $32.18B 78.42%
2018-12-31 $40.83B $31.84B 77.99%
2018-09-30 $53.37B $41.94B 78.59%
2018-06-30 $53.24B $41.66B 78.25%
2018-03-31 $52.67B $41.35B 78.50%
2017-12-31 $52.55B $41.32B 78.63%
2017-09-30 $52.47B $41.29B 78.68%
2017-06-30 $52.35B $40.92B 78.17%
2017-03-31 $52.60B $40.66B 77.30%
2016-12-31 $52.82B $40.50B 76.67%
2016-09-30 $53.24B $40.72B 76.48%
2016-06-30 $52.29B $40.63B 77.71%
2016-03-31 $50.99B $40.33B 79.09%
2015-12-31 $48.85B $39.20B 80.25%
2015-09-30 $47.92B $38.98B 81.35%
2015-06-30 $48.20B $39.11B 81.14%
2015-03-31 $49.12B $39.75B 80.92%
2014-12-31 $49.61B $40.03B 80.69%
2014-09-30 $50.05B $40.38B 80.68%
2014-06-30 $50.33B $40.74B 80.95%
2014-03-31 $50.53B $41.16B 81.46%
2013-12-31 $51.58B $42.00B 81.42%
2013-09-30 $50.88B $41.69B 81.95%
2013-06-30 $51.19B $41.98B 82.02%
2013-03-31 $52.18B $42.84B 82.10%
2012-12-31 $54.66B $44.84B 82.03%
2012-09-30 $53.25B $43.99B 82.61%
2012-06-30 $56.90B $46.54B 81.80%
2012-03-31 $59.42B $47.87B 80.56%
2011-12-31 $61.04B $48.54B 79.52%
2011-09-30 $65.06B $51.27B 78.81%
2011-06-30 $64.44B $50.28B 78.02%
2011-03-31 $65.09B $50.81B 78.06%
2010-12-31 $65.17B $50.38B 77.31%
2010-09-30 $65.50B $50.32B 76.82%
2010-06-30 $61.13B $47.95B 78.44%
2010-03-31 $54.98B $43.73B 79.53%
2009-12-31 $49.27B $40.81B 82.83%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $150.148B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $743.142B 123.75
Novo Nordisk (NVO) Denmark $557.486B 45.93
Johnson & Johnson (JNJ) United States $390.509B 15.54
Merck (MRK) United States $321.545B 84.64
AbbVie (ABBV) United States $316.040B 16.10
Novartis AG (NVS) Switzerland $216.326B 14.99
AstraZeneca (AZN) United Kingdom $200.284B 17.75
Sanofi (SNY) $119.624B 10.77
Innoviva (INVA) United States $0.977B 6.80